New injection fights Hard-to-Treat cancers in early trial
NCT ID NCT06171750
First seen Mar 24, 2026 · Last updated May 23, 2026 · Updated 8 times
Summary
This early-phase study tests a new drug called tolododekin alfa (ANK-101) in people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and tolerable. About 97 adults with various cancers, including lung and skin cancer, will take part. The study also tests the drug combined with another immunotherapy for a type of skin cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Institute
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Providence Cancer Institute
RECRUITINGPortland, Oregon, 97213, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.